13F Holdings
中文EN

OSUR ORASURE TECHNOLOGIES INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1116463 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.5%
TTM net income YoY19.5%
TTM EPS YoY14.8%
Revenue 3-yr CAGR-36.4%
Net income 3-yr CAGR—

Margins

Gross margin43.1%
Operating margin-43.8%
Net margin-41.7%
FCF margin-42.7%
EBITDA margin-35.8%

Returns

ROE-14.5%
ROA-12.6%
ROIC (approx.)-26.4%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets12.1%
Debt / equity0.00x
Current ratio8.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue5.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$115.02M$185.83M$405.47M$387.48M$233.67M
Cost of revenue$66.82M$106.44M$233.82M$239.04M$116.07M
Gross profit$48.20M$79.39M$171.65M$148.44M$117.60M
R&D expense$42.53M$26.05M$33.73M$36.24M$34.17M
SG&A expense$47.68M$46.22M$58.19M$68.21M$50.33M
Operating income-$71.97M-$28.25M$32.68M-$22.16M-$10.16M
Pretax income-$64.59M-$16.00M$56.26M-$15.68M-$9.29M
Income tax$1.80M$1.80M$2.60M$1.46M$13.71M
Net income-$68.73M-$19.50M$53.66M-$17.13M-$23.00M
EBITDA-$61.78M-$17.38M$53.62M-$6.85M$1.49M
EPS (basic)-0.94-0.260.73-0.24-0.32
EPS (diluted)-0.94-0.260.72-0.24-0.32
Weighted avg. shares (diluted)73.48M74.43M74.39M72.50M71.98M
Balance sheet
Cash & equivalents$199.28M$267.76M$290.41M$83.98M$116.76M
Short-term investments——$0$26.87M$36.28M
Receivables$22.20M$23.82M$40.17M$70.80M$45.32M
Inventory$31.06M$34.20M$47.61M$95.70M$53.14M
Current assets$261.91M$333.22M$386.46M$325.19M$299.31M
PP&E, net$39.18M$45.10M$45.42M$59.41M$73.44M
Goodwill$43.36M$40.33M$35.70M$35.10M$40.28M
Intangibles$19.05M$17.43M$1.21M$11.69M$14.34M
Total assets$403.17M$479.66M$482.85M$444.18M$460.99M
Current liabilities$39.80M$33.48M$39.54M$69.06M$68.06M
Total liabilities$62.34M$69.32M$52.17M$79.75M$80.46M
Shareholders' equity$340.83M$410.34M$430.67M$364.43M$380.53M
Shares outstanding70.39M74.60M73.53M72.73M72.07M
Cash flow statement
Operating cash flow-$49.02M$27.37M$141.58M-$47.20M-$35.38M
Capital expenditure$4.20M$3.80M$5.80M$6.77M$21.89M
Free cash flow-$53.22M$23.58M$135.78M-$53.98M-$57.27M
Investing cash flow-$6.81M-$39.03M$66.15M$21.09M-$5.50M
Financing cash flow-$16.94M-$4.18M-$3.02M-$3.83M-$2.82M
Depreciation & amortization$10.19M$10.87M$20.94M$15.31M$11.66M
Stock-based compensation$10.15M$11.92M$10.73M$11.62M$7.81M
Share buybacks$15.04M$0$0$2.25M$2.11M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.